News
Our study examines how RNA in extracellular vesicles (EVs) can provide insights into metabolic phenotypes related to obesity.
14h
The Brighterside of News on MSNWeight-loss drug Tirzepatide significantly slows breast cancer growth, study findsKey Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.
Seoul, Seoul / Syndication Cloud / July 13, 2025 / Lydian Cosmetic Surgery Clinic Key Takeaways: Orthopedic non-invasive stem cell therapy regenerates damaged tissue rather than just improving ...
Emeli Chatterjee, Ph.D., of the Cardiovascular Research Center at Massachusetts General Hospital, is the lead author and ...
Q: How would you summarize your study for a lay audience?Our study examines how RNA in extracellular vesicles (EVs) can provide insights into ...
A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.
Adipose tissue (AT) plays a central role in both metabolic health and pathophysiology. Its expansion in obesity results in increased mortality and morbidity, with contributions to cardiovascular ...
This discovery not only unveils a novel mechanism by which BAT influences liver metabolism but also highlights miR-206-3p as a potential therapeutic ...
Combining ASC47 with semaglutide, the new therapy aims to reshape obesity treatment with targeted, once-monthly injections.
Parade. Body fat gets a bad rap when it comes to health—we're all always on a mission to get rid of belly fat! But it turns ...
Discover how Adipotide, a promising peptide, could revolutionise our understanding of adipose tissue dynamics and metabolic regulation, paving the way for innovative therapies.
Bonus Biogroup (TASE: BONS), a late-stage biotechnology company priming immunomodulatory and regenerative mesenchymal stem cells (MSC) to develop novel tissue engineering and cell therapy solutions, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results